Royal Bank of Canada
CLDX icon

Royal Bank of Canada’s Celldex Therapeutics CLDX Stock Holding History

Royal Bank of Canada’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-153
Closed -$58K – 6647
2015
Q2 		$58K Buy
+153
New +$60.8K ﹤0.01% 5146

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Royal Bank of Canada's CLDX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Celldex Therapeutics (CLDX) stake by 78% in Q1 2026, selling an estimated $48.8K and leaving 502 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #5983.

Royal Bank of Canada first reported a position in CLDX in Q2 2013 and has held it in 50 quarters since. The position peaked at $1.17M in Q3 2025. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Royal Bank of Canada held 502 shares of Celldex Therapeutics worth $16K as of Q1 2026.
  • Royal Bank of Canada sold 1,790 Celldex Therapeutics shares in Q1 2026, an estimated $48.8K.
  • Celldex Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5983 holding.
  • Royal Bank of Canada first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 50 quarters since.
  • Royal Bank of Canada's Celldex Therapeutics position peaked at $1.17M in Q3 2025.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.